Revolution Medicines, Inc. (RVMD) KPIs and segments
Close on Nov 18, 2026Market cap $34.26BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Revolution Medicines · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Revolution Medicines: 34 chỉ số vận hành, trong đó có Cumulative RAS clinical studies registered on, Clinical studies by drug candidate và Cumulative target / actual patient enrollment across, lấy từ 99 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumulative RAS(ON) clinical studies registered on ClinicalTrials.gov (studies)6 | 27.00 | 23.00 | 22.00 | 19.00 | 18.00 | 18.00 | 16.00 | 16.00 | 15.00 | 15.00 | 13.00 | 12.00 | |
New clinical studies initiated / posted in period (studies) | 4.00 | 1.00 | 3.00 | 1.00 | 0.00 | 2.00 | 0.00 | 1.00 | 0.00 | 2.00 | 1.00 | 1.00 | |
By clinical stage — Phase 3 registrational clinical studies (RASolute 302/303/304/305/309, RASolve 301 & RAS-002) (studies) | 7.00 | 5.00 | 4.00 | 3.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
By clinical stage — Phase 1/2 & Phase 2 clinical studies (studies) | 10.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 5.00 | |
By clinical stage — Phase 1 dose-escalation & pharmacology studies (studies) | 10.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | |
By lead sponsor — Revolution Medicines-sponsored clinical studies (studies) | 19.00 | 17.00 | 16.00 | 13.00 | 12.00 | 12.00 | 11.00 | 11.00 | 10.00 | 10.00 | 9.00 | 8.00 | |
By lead sponsor — Collaborative partner & academic investigator-sponsored studies (studies) | 8.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | |
Clinical studies by drug candidate — Daraxonrasib / RASONQUE (RMC-6236, RAS(ON) multi-selective) (studies)4 | 16.00 | 13.00 | 13.00 | 10.00 | 9.00 | 9.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 3.00 | |
Zoldonrasib (RMC-9805, RAS(ON) G12D-selective) clinical studies (studies) | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | |
Elironrasib (RMC-6291, RAS(ON) G12C-selective) clinical studies (studies) | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | |
RMC-5127 (RAS(ON) G12V-selective) clinical studies (studies) | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
RAS companion inhibitors (vociprotafib / RMC-4630 & cobimetinib / RMC-4550) clinical studies (studies) | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | |
Cumulative target / actual patient enrollment across RAS(ON) clinical studies (patients)10 | 10,448.00 | 9,324.00 | 8,654.00 | 6,810.00 | 6,310.00 | 6,310.00 | 5,537.00 | 5,537.00 | 5,037.00 | 5,037.00 | 3,787.00 | 3,171.00 | |
New target / actual patient enrollment added in period (patients) | 1,124.00 | 670.00 | 1,844.00 | 500.00 | 0.00 | 773.00 | 0.00 | 500.00 | 0.00 | 1,250.00 | 616.00 | 534.00 | |
By clinical stage — Phase 3 registrational trial enrollment capacity (patients) | 3,990.00 | 3,160.00 | 2,490.00 | 1,590.00 | 1,090.00 | 1,090.00 | 500.00 | 500.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
By clinical stage — Phase 1 & Phase 1/2/2 trial enrollment capacity (patients) | 6,458.00 | 6,164.00 | 6,164.00 | 5,220.00 | 5,220.00 | 5,220.00 | 5,037.00 | 5,037.00 | 5,037.00 | 5,037.00 | 3,787.00 | 3,171.00 | |
By lead sponsor — Revolution Medicines-sponsored study enrollment (patients) | 9,145.00 | 8,315.00 | 7,645.00 | 5,801.00 | 5,301.00 | 5,301.00 | 4,711.00 | 4,711.00 | 4,211.00 | 4,211.00 | 3,081.00 | 2,465.00 | |
By lead sponsor — Partner & investigator-sponsored study enrollment (patients) | 1,303.00 | 1,009.00 | 1,009.00 | 1,009.00 | 1,009.00 | 1,009.00 | 826.00 | 826.00 | 826.00 | 826.00 | 706.00 | 706.00 | |
By drug candidate — Daraxonrasib / RASONQUE (RMC-6236) study enrollment (patients) | 8,069.00 | 7,375.00 | 7,375.00 | 5,531.00 | 5,031.00 | 5,031.00 | 4,258.00 | 4,258.00 | 3,758.00 | 3,758.00 | 2,508.00 | 1,892.00 | |
By drug candidate — Zoldonrasib (RMC-9805) study enrollment (patients) | 4,403.00 | 3,573.00 | 2,903.00 | 2,533.00 | 2,533.00 | 2,533.00 | 2,350.00 | 2,350.00 | 2,350.00 | 2,350.00 | 1,220.00 | 604.00 | |
By drug candidate — Elironrasib (RMC-6291) study enrollment (patients) | 1,742.00 | 1,742.00 | 1,742.00 | 1,372.00 | 1,372.00 | 1,372.00 | 1,372.00 | 1,372.00 | 1,372.00 | 1,372.00 | 1,372.00 | 756.00 | |
By drug candidate — RMC-5127 study enrollment (patients) | 574.00 | 574.00 | 574.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
By drug candidate — RAS companion inhibitors (RMC-4630 & RMC-4550) study enrollment (patients) | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | 1,057.00 | |
Total research and development (R&D) expenses ($M)($M)5 | 417 | 395 | 344 | 295 | 263 | 224 | 206 | 188 | 152 | 135 | 118 | 148 | |
Third-party external R&D expenses — Total clinical & preclinical programs ($M)($M)6 | 255 | 233 | 209 | 184 | 170 | 144 | 133 | 122 | 95.6 | 81.7 | 69.3 | 90.0 | |
Daraxonrasib / RASONQUE (RMC-6236, RAS(ON) multi-selective inhibitor) external R&D ($M)($M) | 121 | 114 | 114 | 95.1 | 91.5 | 76.9 | 67.5 | 61.4 | 50.5 | 30.2 | 27.0 | 44.5 | |
Zoldonrasib (RMC-9805, RAS(ON) G12D-selective inhibitor) external R&D ($M)($M) | 78.1 | 64.0 | 52.1 | 41.3 | 30.9 | 23.5 | 24.5 | 24.1 | 13.2 | 14.7 | 12.0 | 10.7 | |
Elironrasib (RMC-6291, RAS(ON) G12C-selective inhibitor) external R&D ($M)($M) | 13.0 | 12.2 | 15.0 | 18.0 | 18.5 | 18.2 | 19.0 | 18.2 | 11.2 | 15.8 | 9.93 | 9.79 | |
RMC-5127 (RAS(ON) G12V-selective inhibitor) external R&D ($M)($M) | 9.82 | 8.90 | 3.41 | 4.55 | 4.45 | 2.33 | 1.49 | 0 | 0 | 0 | 0 | 0 | |
RAS companion inhibitors (vociprotafib / RMC-4630 & cobimetinib / RMC-4550) external R&D ($M)($M) | 0.07 | 0.15 | 0.05 | 0.22 | 0.03 | 0.07 | 0.43 | 1.07 | 1.98 | 1.60 | 2.31 | 2.60 | |
Other research and preclinical discovery programs external R&D ($M)($M) | 32.9 | 34.0 | 24.1 | 25.2 | 24.6 | 23.1 | 19.9 | 16.8 | 18.8 | 19.4 | 18.1 | 22.3 | |
Unallocated internal R&D — Personnel salaries and benefits (excl. SBC) ($M)($M) | 76.9 | 78.6 | 61.5 | 63.8 | 46.9 | 41.2 | 37.2 | 35.2 | 27.4 | 26.3 | 25.2 | 32.3 | |
Unallocated internal R&D — Stock-based compensation expense ($M)($M) | 36.8 | 39.3 | 44.6 | 22.5 | 20.3 | 19.1 | 16.4 | 14.6 | 13.4 | 12.8 | 10.2 | 12.6 | |
Unallocated internal R&D — Intangible asset amortization ($M)($M) | 0 | 0 | 0 | 0.07 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | |
Unallocated internal R&D — Facilities, lab supplies, depreciation and other ($M)($M) | 48.2 | 44.0 | 29.1 | 24.1 | 25.0 | 19.4 | 19.2 | 16.5 | 15.1 | 13.9 | 13.1 | 13.3 | |
Selling, general and administrative (SG&A) expenses ($M)($M)1 | 153 | 110 | 101 | 66.7 | 52.8 | 40.6 | 35.0 | 28.2 | 24.0 | 21.7 | 22.8 | 32.2 | |
SG&A stock-based compensation expense ($M)($M) | 25.3 | 27.7 | 42.7 | 11.2 | 10.4 | 9.70 | 8.70 | 7.86 | 7.41 | 7 | 5.96 | 12.8 | |
Full-year GAAP operating expense guidance — Upper bound ($M)($M)5 | 2,200 | 2,200 | 1,800 | 1,700 | |||||||||
Full-year GAAP operating expense guidance — Lower bound ($M)($M) | 2,100 | 2,100 | 1,700 | 1,600 | |||||||||
Full-year stock-based compensation guidance — Upper bound ($M)($M) | 290 | 290 | 280 | 200 | 130 | 130 | 130 | 130 | 80 | 80 | 80 | 80 | |
Full-year stock-based compensation guidance — Lower bound ($M)($M) | 270 | 270 | 260 | 180 | 115 | 115 | 115 | 115 | 70 | 70 | 70 | 70 | |
Historical full-year GAAP net loss guidance — Upper bound ($M)($M) | 1,090 | 1,090 | 900 | 900 | 600 | 600 | 520 | 520 | |||||
Historical full-year GAAP net loss guidance — Lower bound ($M)($M) | 1,030 | 1,030 | 840 | 840 | 560 | 560 | 480 | 480 | |||||
Revenue from contracts with customers & collaboration arrangements ($M)($M)1 | 198 | 0 | 0 | 0 | 0 | 0 | 0 | 0.74 | |||||
Historical deferred collaboration revenue, current ($M)($M) | 0 | ||||||||||||
Royalty Pharma synthetic royalty financing — Ending liability carrying value ($M)($M)5 | 572 | 549 | 281 | 268 | 257 | 245 | 0 | 0 | 0 | 0 | 0 | 0 | |
Royalty monetization gross cash proceeds received in period ($M)($M) | 0 | 250 | 0 | 0 | 0 | 250 | 0 | 0 | 0 | 0 | 0 | 0 | |
Royalty monetization net cash proceeds (after issuance costs) ($M)($M) | 0 | 0 | -5.79 | 0 | 0 | ||||||||
Royalty monetization non-cash imputed interest expense ($M)($M) | 32.2 | 22.5 | 12.0 | 11.7 | 11.2 | 0.85 | 0 | 0 | 0 | 0 | 0 | 0 | |
Royalty monetization amortization of debt issuance costs ($M)($M) | 0.57 | 0.42 | 0.24 | 0.26 | 0.27 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cumulative upfront cash received under Royalty Pharma agreement ($M)($M) | 250 | 250 | 250 | ||||||||||
2033 Convertible Senior Notes — Carrying value (net of unamortized issuance costs) ($M)($M) | 488 | 487 | 0.24 | 0 | 0.27 | ||||||||
Assumed EQRx warrant liabilities — Total fair value ($M)($M)10 | 224 | 185 | 34.3 | 18.6 | 5.92 | 5.33 | 0.75 | 3.19 | 2.76 | 1.41 | 3.16 | 6.51 | |
Public warrant liability — Level 1 quoted market fair value ($M)($M) | 125 | 104 | 19.2 | 10.4 | 3.31 | 2.98 | 0.42 | 1.78 | 1.55 | 0.79 | 1.77 | 3.64 | |
Private placement warrant liability — Level 3 Black-Scholes fair value ($M)($M) | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0.21 | 0.29 | 0.45 | 1 | |
Warrant liability — Level 2 observable market fair value ($M)($M) | 99.6 | 81.7 | 15.1 | 8.17 | 2.61 | 2.35 | 0.33 | 1.41 | 1.22 | 0.62 | 1.39 | 2.87 | |
Change in fair value of warrant liabilities recognized in earnings ($M)($M) | 40.7 | 151 | 15.8 | 12.6 | 0.59 | 4.58 | -2.44 | 0.22 | 1.27 | -1.91 | -3.90 | 0.12 | |
Combined change in fair value of warrant and earn-out liabilities ($M)($M) | -12.6 | -0.59 | -4.58 | 2.44 | -0.22 | -1.27 | 1.91 | 3.90 | 0.12 | ||||
Underlying RVMD common shares issuable — Public warrants (M shares)(M) | 11.0 | 11.0 | 11.0 | 11.0 | 11.0 | 11.0 | |||||||
Underlying RVMD common shares issuable — Private placement warrants (M shares)(M) | 8.69 | 8.69 | 8.69 | 8.69 | 8.69 | 8.69 | |||||||
Common shares issued upon warrant exercises in period (M shares)(M) | 0.02 | 0.00 | 0 | 0 | 0 | ||||||||
Equity value credited from warrant exercises ($M)($M) | 3.43 | 0.35 | 0.06 | 0 | 0 | ||||||||
Cash proceeds from exercise of warrants ($M)($M) | 1.78 | 0.24 | 0.06 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Cash equivalents & AFS marketable securities portfolio — Total fair value ($M)($M)4 | 3,576 | 3,883 | 1,859 | 2,024 | 1,932 | 2,136 | 2,104 | 2,287 | 1,547 | 1,584 | 1,704 | 1,853 | |
Marketable securities portfolio — Total fair value ($M)($M)4 | 3,035 | 3,123 | 1,467 | 1,642 | 1,714 | 1,735 | 1,769 | 1,746 | 1,348 | 1,315 | 1,415 | 1,157 | |
Marketable securities — U.S. government & agency securities fair value ($M)($M) | 1,194 | 1,163 | 590 | 691 | 699 | 854 | 934 | 1,012 | 794 | 697 | 781 | 611 | |
Marketable securities — Commercial paper fair value ($M)($M) | 230 | 252 | 44.9 | 62.4 | 105 | 122 | 148 | 159 | 143 | 254 | 410 | 461 | |
Marketable securities — Corporate debt securities fair value ($M)($M) | 1,612 | 1,707 | 832 | 889 | 908 | 755 | 684 | 567 | 402 | 351 | 216 | 85.2 | |
Marketable securities — Certificates of deposit fair value ($M)($M) | 2.58 | 3.83 | 3.84 | 9.05 | 9.37 | 12.7 | 8.57 | ||||||
Cash equivalents portfolio — Total fair value ($M)($M)4 | 541 | 760 | 392 | 382 | 218 | 402 | 335 | 541 | 199 | 269 | 288 | 696 | |
Cash equivalents — Money market funds fair value ($M)($M) | 379 | 437 | 369 | 369 | 186 | 351 | 247 | 409 | 136 | 121 | 191 | 289 | |
Cash equivalents — Commercial paper fair value ($M)($M) | 162 | 317 | 22.9 | 12.7 | 22.4 | 37.1 | 63 | 86.8 | 44.9 | 105 | 69.8 | 231 | |
Cash equivalents — U.S. government & agency securities fair value ($M)($M) | 0 | 1.15 | 8.70 | 14.0 | 23.8 | 40.0 | 17.9 | 43.6 | 27.7 | 176 | |||
Cash equivalents — Corporate debt securities fair value ($M)($M) | 0 | 5.50 | 0.20 | 1.26 | 0 | 1.23 | 5.12 | ||||||
By contractual maturity — Debt securities maturing within 1 year fair value ($M)($M) | 2,433 | 2,466 | 1,460 | 1,543 | 1,431 | 1,695 | 1,695 | 1,910 | 1,390 | 1,384 | 1,424 | 1,684 | |
By contractual maturity — Debt securities maturing in 1 to 2 years fair value ($M)($M) | 1,144 | 1,417 | 399 | 481 | 501 | 442 | 410 | 377 | 157 | 200 | 279 | 169 | |
Cash equivalents & AFS marketable securities portfolio — Total amortized cost ($M)($M)6 | 3,591 | 3,889 | 1,860 | 2,021 | 1,929 | 2,135 | 2,103 | 2,286 | 1,544 | 1,586 | 1,705 | 1,852 | |
Marketable securities portfolio — Total amortized cost ($M)($M)4 | 3,050 | 3,128 | 1,468 | 1,639 | 1,711 | 1,733 | 1,767 | 1,745 | 1,344 | 1,317 | 1,416 | 1,156 | |
Marketable securities — U.S. government & agency securities amortized cost ($M)($M) | 1,201 | 1,165 | 590 | 689 | 698 | 853 | 933 | 1,011 | 791 | 698 | 782 | 610 | |
Marketable securities — Commercial paper amortized cost ($M)($M) | 230 | 253 | 44.9 | 62.4 | 105 | 122 | 148 | 159 | 143 | 254 | 410 | 461 | |
Marketable securities — Corporate debt securities amortized cost ($M)($M) | 1,619 | 1,710 | 833 | 887 | 906 | 754 | 683 | 566 | 401 | 351 | 216 | 85.0 | |
Marketable securities — Certificates of deposit amortized cost ($M)($M) | 2.58 | 3.83 | 3.83 | 9.04 | 9.34 | 12.7 | 8.58 | ||||||
Cash equivalents portfolio — Total amortized cost ($M)($M)4 | 541 | 760 | 392 | 382 | 218 | 402 | 335 | 541 | 199 | 269 | 288 | 696 | |
Cash equivalents — Money market funds amortized cost ($M)($M) | 379 | 437 | 369 | 369 | 186 | 351 | 247 | 409 | 136 | 121 | 191 | 289 | |
Cash equivalents — Commercial paper amortized cost ($M)($M) | 162 | 317 | 22.9 | 12.7 | 22.4 | 37.1 | 63.0 | 86.8 | 44.9 | 105 | 69.8 | 231 | |
Cash equivalents — U.S. government & agency securities amortized cost ($M)($M) | 0 | 1.15 | 8.70 | 14.0 | 23.8 | 40.0 | 17.9 | 43.6 | 27.7 | 176 | |||
Cash equivalents — Corporate debt securities amortized cost ($M)($M) | 0 | 5.50 | 0.20 | 1.26 | 0 | 1.23 | 5.12 | ||||||
By contractual maturity — Debt securities maturing within 1 year amortized cost ($M)($M) | 2,438 | 2,468 | 1,460 | 1,541 | 1,429 | 1,694 | 1,694 | 1,909 | 1,387 | 1,385 | 1,425 | 1,684 | |
By contractual maturity — Debt securities maturing in 1 to 2 years amortized cost ($M)($M) | 1,152 | 1,421 | 400 | 480 | 500 | 441 | 409 | 377 | 157 | 201 | 280 | 168 | |
AFS portfolio gross unrealized gains — Total ($M)($M)2 | 0.01 | 0.15 | 0.68 | 3.28 | 3.20 | 1.59 | 1.97 | 1.87 | 3.87 | 0.07 | 0.17 | 1.10 | |
Marketable securities — Gross unrealized gains ($M)($M) | 0.01 | 0.15 | 0.68 | 3.28 | 3.20 | 1.97 | 1.86 | 3.87 | 0.07 | 0.17 | 1.07 | ||
Cash equivalents — Gross unrealized gains ($M)($M) | 0.00 | 0.00 | 0 | 0 | 0.00 | 0 | 0.00 | 0.00 | 0 | 0 | 0.04 | ||
AFS portfolio gross unrealized losses — Total ($M)($M)2 | 14.5 | 6 | 1.29 | 0.04 | 0.08 | 0.29 | 0.26 | 0.55 | 0.06 | 1.94 | 1.37 | 0.56 | |
Marketable securities — Gross unrealized losses ($M)($M) | 14.5 | 5.96 | 1.29 | 0.04 | 0.08 | 0.29 | 0.25 | 0.53 | 0.06 | 1.88 | 1.33 | 0.46 | |
Cash equivalents — Gross unrealized losses ($M)($M) | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.06 | 0.04 | 0.10 | |
Financial assets measured at fair value on a recurring basis — Total ($M)($M)8 | 3,576 | 3,883 | 1,859 | 2,024 | 1,932 | 2,136 | 2,104 | 2,287 | 1,547 | 1,584 | 1,704 | 1,853 | |
Fair value hierarchy — Level 1 (quoted prices in active markets) ($M)($M) | 379 | 437 | 369 | 369 | 186 | 351 | 247 | 409 | 136 | 121 | 191 | 289 | |
Fair value hierarchy — Level 2 (significant observable market inputs) ($M)($M) | 3,197 | 3,446 | 1,490 | 1,655 | 1,746 | 1,786 | 1,857 | 1,878 | 1,411 | 1,463 | 1,513 | 1,564 | |
Fair value hierarchy — Level 3 (unobservable inputs) ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
By instrument class — Money market funds (Level 1) ($M)($M) | 379 | 437 | 369 | 369 | 186 | 351 | 247 | 409 | 136 | 121 | 191 | 289 | |
By instrument class — U.S. government & agency securities ($M)($M) | 1,194 | 1,164 | 590 | 691 | 708 | 868 | 958 | 1,052 | 811 | 741 | 808 | 786 | |
By instrument class — Commercial paper ($M)($M) | 391 | 570 | 67.7 | 75.1 | 127 | 159 | 211 | 246 | 188 | 359 | 480 | 692 | |
By instrument class — Corporate debt securities ($M)($M) | 1,612 | 1,713 | 832 | 889 | 909 | 755 | 685 | 572 | 402 | 351 | 216 | 85.2 | |
By instrument class — Certificates of deposit ($M)($M) | 2.58 | 3.83 | 3.84 | 9.05 | 9.37 | 12.7 | 8.57 | ||||||
Cash, cash equivalents and restricted cash — Ending balance ($M)($M)6 | 632 | 820 | 446 | 389 | 222 | 406 | 337 | 547 | 204 | 279 | 291 | 699 | |
Restricted cash, current ($M)($M) | 15.8 | 4.86 | 4.86 | 4.86 | 4.86 | 3.92 | 3.70 | 3.70 | 2.89 | 3.03 | 3.03 | 3.03 | |
Restricted cash, non-current (facility letters of credit) ($M)($M) | 15.8 | 4.86 | 4.86 | 4.86 | 4.86 | 3.92 | 3.70 | 3.70 | 2.89 | 3.03 | 3.03 | 3.03 | |
Purchases of marketable securities ($M)($M) | 541 | 2,038 | 210 | 296 | 459 | 529 | 510 | 695 | 365 | 375 | 702 | 520 | |
Proceeds from maturities and sales of marketable securities ($M)($M) | 9.44 | 382 | 384 | 0 | 0 | 565 | 497 | 0 | 0 | 485 | 457 | 142 | |
Net amortization (accretion) of discount on marketable securities ($M)($M) | 5.46 | 4.33 | 3.22 | 4.55 | 5.72 | 7.74 | 9.82 | 8.83 | 9.59 | 10.9 | 15.2 | 8.63 | |
Other comprehensive income (loss) — Unrealized gain (loss) on marketable securities ($M)($M) | -8.62 | -5.24 | -3.85 | 0.12 | 1.81 | -0.41 | 0.39 | -2.49 | 5.67 | -0.67 | -1.74 | 1.42 | |
Total stock-based compensation (SBC) expense ($M)($M)5 | 62.6 | 67 | 87.3 | 33.7 | 30.8 | 28.8 | 25.1 | 22.4 | 20.8 | 19.8 | 16.2 | 25.4 | |
SBC expense allocated to Research and Development ($M)($M) | 36.8 | 39.3 | 44.6 | 22.5 | 20.3 | 19.1 | 16.4 | 14.6 | 13.4 | 12.8 | 10.2 | 12.6 | |
SBC expense allocated to Selling, General and Administrative ($M)($M) | 25.3 | 27.7 | 42.7 | 11.2 | 10.4 | 9.70 | 8.70 | 7.86 | 7.41 | 7 | 5.96 | 12.8 | |
Unrecognized SBC cost — Nonvested stock options ($M)($M)1 | 268 | 277 | 288 | 208 | 178 | 179 | 180 | 119 | 121 | 119 | 123 | 79.5 | |
Weighted-average remaining recognition period — Stock options (years)(năm) | 2.9 | 3.0 | 3.0 | 2.7 | 2.8 | 2.9 | 3.0 | 2.7 | 2.8 | 2.9 | 3.1 | 2.8 | |
Unrecognized SBC cost — Nonvested restricted stock units (RSUs & PSUs) ($M)($M)1 | 337 | 304 | 278 | 150 | 129 | 127 | 126 | 82.9 | 81 | 79.5 | 81.5 | 51 | |
Weighted-average remaining recognition period — RSUs & PSUs (years)(năm) | 3.3 | 3.3 | 3.3 | 2.8 | 2.9 | 3.0 | 3.1 | 2.8 | 2.9 | 3.1 | 3.2 | 3.0 | |
Unrecognized SBC cost — Employee Stock Purchase Plan (ESPP) ($M)($M) | 11.1 | 13.7 | 0.90 | 5.30 | 2.20 | 3.20 | 4 | 4.90 | 6 | 7.10 | 2.50 | 3.30 | |
Stock options outstanding — Ending shares (M shares)(M)8 | 17.7 | 18.4 | 19.4 | 18 | 17.7 | 17.3 | 16.7 | 14.0 | 14.1 | 13.8 | 13.8 | 11.1 | |
Stock options outstanding — Weighted-average exercise price ($/sh)($) | 43.13 | 40.42 | 37.52 | 30.45 | 28.23 | 27.64 | 27.17 | 24.25 | 23.14 | 22.19 | 21.76 | 19.64 | |
Stock options outstanding — Weighted-average remaining contractual term (years)(năm) | 7.1 | 7.3 | 7.4 | 7.3 | 7.3 | 7.5 | 7.6 | 7.4 | 7.5 | 7.6 | 7.8 | 7.5 | |
Stock options outstanding — Aggregate intrinsic value ($M)($M) | 2,870 | 2,697 | 1,169 | 885 | 328 | 185 | 171 | 276 | 313 | 233 | 154 | 115 | |
Stock options exercisable — Weighted-average exercise price ($/sh)($) | 27.51 | 25.62 | 23.71 | 23.05 | 22.17 | 21 | 19.80 | 19.04 | 17.88 | 16.88 | 15.71 | 14.92 | |
Stock options exercisable — Weighted-average remaining contractual term (years)(năm) | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.1 | 6.2 | 6.2 | 6.2 | 6.3 | 6.2 | 6.4 | |
Stock options exercisable — Aggregate intrinsic value ($M)($M) | 1,764 | 1,575 | 742 | 548 | 233 | 148 | 134 | 189 | 203 | 155 | 113 | 92.5 | |
Stock options granted in period (M shares)(M) | 0.22 | 0.34 | 1.95 | 1.06 | 0.71 | 0.78 | 2.86 | 0.36 | 0.61 | 0.35 | 2.86 | 0.40 | |
Stock options exercised in period (M shares)(M)1 | 0.82 | 1.31 | 0.47 | 0.65 | 0.29 | 0.12 | 0.09 | 0.40 | 0.22 | 0.24 | 0.07 | 0.21 | |
Proceeds / equity value from stock options exercised ($M)($M) | 19.5 | 28.8 | 12.2 | 4.14 | 1.94 | 0.89 | 3 | 4.34 | 0.81 | ||||
Nonvested restricted stock units (RSUs & PSUs) outstanding — Ending shares (M shares)(M)6 | 4.83 | 5.08 | 5.14 | 3.89 | 3.84 | 3.81 | 3.84 | 2.85 | 2.97 | 3.03 | 3.21 | 2.16 | |
Nonvested RSUs & PSUs — Weighted-average grant-date fair value ($/sh)($) | 78.51 | 67.82 | 59.18 | 39.16 | 35.80 | 35.20 | 34.50 | 30.87 | 28.80 | 27.53 | 26.90 | 25.10 | |
Nonvested RSUs & PSUs — Weighted-average remaining recognition term (years)(năm) | 1.6 | 1.6 | 1.7 | 1.5 | 1.5 | 1.6 | 1.6 | 1.5 | 1.6 | 1.6 | 1.7 | 1.6 | |
Nonvested RSUs & PSUs — Aggregate intrinsic value ($M)($M) | 991 | 951 | 500 | 310 | 179 | 140 | 136 | 125 | 135 | 118 | 103 | 62.0 | |
RSUs & PSUs granted in period (M shares)(M) | 0.34 | 0.41 | 1.65 | 0.47 | 0.41 | 0.40 | 1.28 | 0.21 | 0.25 | 0.17 | 1.25 | 0.24 | |
RSUs & PSUs vested in period (M shares)(M) | 0.55 | 0.40 | 0.37 | 0.37 | 0.34 | 0.36 | 0.27 | 0.29 | 0.26 | 0.30 | 0.17 | 0.16 | |
RSUs & PSUs forfeited / canceled in period (M shares)(M) | 0.04 | 0.08 | 0.03 | 0.05 | 0.03 | 0.07 | 0.01 | 0.04 | 0.06 | 0.04 | 0.03 | 0.02 | |
Common stock reserved for future issuance — Total across all plans & warrants (M shares)(M)9 | 7.13 | 7.13 | 7.33 | 28.7 | 5.79 | 5.79 | 5.63 | 31.7 | 3.85 | 3.85 | 33.2 | 31.7 | |
Shares reserved — Outstanding stock options & unvested RSUs/PSUs (M shares)(M) | 17.7 | 18.4 | 19.4 | 18 | 17.7 | 17.3 | 14.0 | 14.1 | 13.8 | 16.7 | 14.0 | ||
Shares reserved — Available for future grant under 2020 Equity Incentive Plan (M shares)(M) | 6.69 | 7.15 | 7.71 | 1.40 | 2.81 | 3.85 | 8.95 | 9.41 | 10.1 | 4.84 | 8.95 | ||
Shares reserved — Available for future issuance under 2020 ESPP (M shares)(M) | 7.13 | 7.13 | 7.33 | 5.36 | 5.79 | 5.79 | 3.78 | 3.85 | 3.85 | 5.63 | 3.78 | ||
Net cash proceeds from common stock & pre-funded warrant offerings ($M)($M) | -1,384 | 142 | 142 | 0 | 0 | 728 | 0 | 0 | 0 | 0 | |||
Net cash proceeds from At-the-Market (ATM) equity offerings ($M)($M) | 126 | 0 | 227 | 348 | 0 | 0 | 0 | 44.4 | 74.3 | 0 | |||
Common shares issued under ATM equity programs (M shares)(M) | 0.62 | 0 | 2.33 | 0 | 1.63 | 0 | |||||||
Net equity value raised under ATM equity programs ($M)($M) | 126 | 227 | 74.3 | ||||||||||
Cash proceeds from issuance of common stock under employee equity plans ($M)($M) | 19.5 | 28.8 | 12.2 | 4.14 | 1.94 | 0.89 | 4.18 | 3 | 4.34 | 0.81 | 1.34 | ||
Cash proceeds from issuance of common stock under ESPP ($M)($M) | 0 | 3.39 | 0 | 1.86 | 0 | 1.21 | |||||||
Potentially dilutive securities excluded from diluted net loss per share — Total (M shares)(M)6 | 27.3 | 28.2 | 27.1 | 24.5 | 24.2 | 24.0 | 23.3 | 19.4 | 20.6 | 20.4 | 20.3 | 16.6 | |
Antidilutive securities — Stock options outstanding (M shares)(M) | 17.7 | 18.4 | 19.4 | 18 | 17.7 | 17.3 | 16.7 | 14.0 | 14.1 | 13.8 | 13.8 | 11.1 | |
Antidilutive securities — Unvested RSUs and PSUs (M shares)(M) | 4.83 | 5.08 | 5.14 | 3.89 | 3.84 | 3.81 | 3.84 | 2.85 | 2.97 | 3.03 | 3.21 | 2.16 | |
Antidilutive securities — Assumed EQRx public and private warrants (M shares)(M) | 2.17 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | 2.19 | |
Antidilutive securities — Shares committed under ESPP (M shares)(M) | 0.06 | 0.09 | 0.30 | 0.43 | 0.55 | 0.70 | 0.50 | 0.40 | 0.35 | 0.41 | 0.21 | 0.23 | |
Antidilutive securities — Historical EQRx earn-out shares (M shares)(M) | 0 | 0 | 0 | 0 | 0 | 0.97 | 0.97 | 0.97 | 0.97 | ||||
Antidilutive securities — Common stock subject to repurchase from early-exercised options (M shares)(M) | 0 | 0 | 0 | 0 | |||||||||
Operating lease liabilities — Total carrying value ($M)($M)12 | 151 | 154 | 157 | 159 | 158 | 133 | 134 | 136 | 86.7 | 87.4 | 88.0 | 87.9 | |
Operating lease liabilities, current ($M)($M) | 9.38 | 16.8 | 16.6 | 16.5 | 16.3 | 13.1 | 13.0 | 12.9 | 8.40 | 8.33 | 8.17 | 7.37 | |
Operating lease liabilities, non-current ($M)($M) | 142 | 138 | 140 | 142 | 142 | 120 | 121 | 123 | 78.3 | 79.1 | 79.9 | 80.6 | |
Operating lease right-of-use (ROU) assets ($M)($M) | 125 | 128 | 130 | 132 | 134 | 114 | 116 | 118 | 74.3 | 75.3 | 76.2 | 77.2 | |
Operating leases — Weighted-average remaining lease term (years)(năm) | 9.3 | 9.5 | 9.8 | 10.0 | 10.3 | 10.5 | 10.8 | 11.0 | 11.3 | 11.6 | 11.8 | 12.0 | |
Operating leases — Weighted-average discount rate (%)(%) | 8.0% | 8.0% | 8.0% | 8.0% | 8.0% | 7.6% | 7.7% | 7.7% | 8.4% | 8.4% | 8.4% | 8.4% | |
Operating lease cost recognized in period ($M)($M) | 5.42 | 5.30 | 5.39 | 4.19 | 5.55 | 4.26 | 4.82 | 3.77 | 2.80 | 2.80 | 2.80 | 2.80 | |
Total lease cost (operating & variable lease cost) ($M)($M) | 4.20 | 4.12 | 4.20 | 3.35 | 4.92 | 3.65 | 3.56 | 3.21 | 2.80 | 2.80 | 2.80 | 2.80 | |
Non-cash amortization of operating lease right-of-use assets ($M)($M) | 2.45 | 2.05 | 2.19 | 2.37 | 2.01 | 1.78 | 1.76 | 1.39 | 0.97 | 0.89 | 0.96 | 1.24 | |
Sublease income ($M)($M) | 1.22 | 1.19 | 1.19 | 0.83 | 0.63 | 0.61 | 1.27 | 0.56 | 0 | 0 | 0 | 0 | |
Standby letters of credit securing Redwood City campus leases ($M)($M) | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 3.70 | 3.70 | 3.70 | 2.90 | 2.40 | 2.40 | 2.40 | |
Security deposits and other non-current deposits ($M)($M) | 65.7 | 42.5 | 34.7 | 24.2 | 16.9 | 12.1 | |||||||
Undiscounted future minimum operating lease payments — Total ($M)($M)7 | 219 | 229 | 234 | 239 | 244 | 205 | 209 | 216 | 139 | 141 | 144 | 145 | |
Lease maturity schedule — Remainder of current fiscal year ($M)($M) | 4.29 | 10.7 | 16.0 | 5.86 | 10.0 | 14.1 | 0.94 | 3.83 | 6.01 | ||||
Lease maturity schedule — Next 12 months / Year 1 ($M)($M) | 16.5 | 20.2 | 20.2 | 21.0 | 19.6 | 17.1 | 17.1 | 18.1 | 10.5 | 10.5 | 10.5 | 7.77 | |
Lease maturity schedule — Year 2 ($M)($M) | 21.9 | 21.9 | 21.9 | 20.2 | 20.2 | 17.6 | 17.6 | 17.1 | 10.8 | 10.8 | 10.8 | 10.5 | |
Lease maturity schedule — Year 3 ($M)($M) | 22.6 | 22.6 | 22.6 | 21.9 | 21.9 | 17.7 | 17.7 | 17.6 | 11.2 | 11.2 | 11.2 | 10.8 | |
Lease maturity schedule — Year 4 ($M)($M) | 23.4 | 23.4 | 23.4 | 22.6 | 22.6 | 18.3 | 18.3 | 17.7 | 11.6 | 11.6 | 11.6 | 11.2 | |
Lease maturity schedule — Thereafter (quarterly 10-Q schedule) ($M)($M) | 130 | 130 | 130 | 153 | 124 | 124 | 93.5 | 93.5 | 93.5 | ||||
Less: Imputed interest on operating lease payments ($M)($M) | 67.4 | 70.2 | 73.3 | 76.3 | 74.3 | 65.3 | 67.8 | 73.7 | 51.9 | 54.1 | 55.6 | 57.5 | |
Property and equipment, net ($M)($M)4 | 34.6 | 34.6 | 31.5 | 33.2 | 32.9 | 33.1 | 27.2 | 24.3 | 24.8 | 25.3 | 23.7 | 22.9 | |
Property and equipment, gross ($M)($M)5 | 69.7 | 67.5 | 62.2 | 61.7 | 59.9 | 58.1 | 50.5 | 46.1 | 46.5 | 45.7 | 42.6 | 40.6 | |
PP&E by asset class — Laboratory equipment ($M)($M) | 37.5 | 35.5 | 30.7 | 30.1 | 28.5 | 28.1 | 26.1 | 25.2 | 24.5 | 24.6 | 22.4 | 21.5 | |
PP&E by asset class — Leasehold improvements ($M)($M) | 22.7 | 22.6 | 22.2 | 22.3 | 21.5 | 21.3 | 14.6 | 14.3 | 14.1 | 14.0 | 13.1 | 12.0 | |
PP&E by asset class — Computer equipment and software ($M)($M) | 7.27 | 7.28 | 7.24 | 7.32 | 7.35 | 6.54 | 5.39 | 5.05 | 6.97 | 6.31 | 5.97 | 5.81 | |
PP&E by asset class — Furniture and fixtures ($M)($M) | 1.95 | 1.95 | 1.95 | 1.96 | 1.96 | 1.66 | 1.31 | 1.20 | 0.80 | 0.84 | 0.78 | 0.78 | |
PP&E by asset class — Construction in progress ($M)($M) | 0.30 | 0.11 | 0.10 | 0.05 | 0.67 | 0.50 | 3.17 | 0.39 | 0.09 | 0.01 | 0.33 | 0.51 | |
Less: Accumulated depreciation and amortization ($M)($M) | 35.1 | 32.8 | 30.7 | 28.5 | 27.0 | 25.0 | 23.4 | 21.8 | 21.7 | 20.5 | 18.9 | 17.7 | |
Depreciation expense on property and equipment ($M)($M) | 2.30 | 2.10 | 2.20 | 2.10 | 2 | 1.70 | 1.60 | 1.40 | 1.60 | 1.60 | 1.50 | 1.30 | |
Non-cash investing activity — Property and equipment purchases in accounts payable & accrued expenses ($M)($M) | -1.36 | 3 | 0.79 | 0.45 | -1.49 | 0.12 | 2.79 | 0.96 | -2.15 | 0.87 | 1.89 | 1.28 | |
Goodwill & acquired intangible assets — Total net intangible assets ($M)($M)5 | 55.5 | 55.8 | 55.8 | 55.8 | 55.9 | 56.1 | 56.4 | 56.7 | 56.9 | 57.2 | 57.5 | 57.7 | |
Goodwill carrying value (from Warp Drive Bio acquisition) ($M)($M) | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | |
Total intangible assets, gross carrying amount ($M)($M) | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | 63.3 | ||
Finite-lived intangible assets, net ($M)($M)2 | 55.5 | 0 | 0 | 0 | 0.07 | 0.34 | 0.60 | 0.87 | 1.14 | 1.41 | 1.67 | 1.94 | |
Finite-lived intangible assets, gross ($M)($M) | 63.3 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | |
Finite-lived intangible assets — Accumulated amortization ($M)($M) | 7.81 | 7.48 | 7.48 | 7.48 | 7.41 | 7.14 | 6.88 | 6.61 | 6.34 | 6.08 | 5.81 | 5.54 | |
Indefinite-lived in-process R&D (IPR&D) intangible assets ($M)($M) | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | 55.8 | ||
Amortization of intangible assets recognized in period ($M)($M) | 0.30 | 0 | 0 | 0.10 | 0.27 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | |
Accrued expenses and other current liabilities — Total ($M)($M)5 | 366 | 249 | 192 | 209 | 154 | 115 | 98.1 | 96.6 | 78.0 | 67.7 | 53.2 | 74.7 | |
Accrued clinical trial and research & development expenses ($M)($M) | 212 | 170 | 158 | 137 | 112 | 89.6 | 81.6 | 63.6 | 55.2 | 49.7 | 40.6 | 45 | |
Accrued employee compensation and benefits ($M)($M) | 64.2 | 64.7 | 23.3 | 58.2 | 31.8 | 21.7 | 13.5 | 30.8 | 19.1 | 14.7 | 9.79 | 23.6 | |
Accrued professional services and other current liabilities ($M)($M) | 21.6 | 8.94 | 7.91 | 6.14 | 2.36 | 2.91 | 2.43 | 1.62 | 2.46 | 2.60 | 2.05 | 2.18 | |
Prepaid expenses and other current assets ($M)($M) | 83.6 | 90.4 | 59.8 | 49.4 | 46.0 | 39.3 | 31.9 | 38.3 | 29.7 | 34.0 | 25.7 | 25.1 | |
Other non-current assets ($M)($M) | 15.2 | 14.8 | 14.5 | 14.8 | 14.9 | 31.4 | 13.1 | 1.74 | 10.3 | 8.27 | 4.16 | 7.03 | |
Income taxes — Gross deferred tax assets (before valuation allowance) ($M)1 | |||||||||||||
Net non-current deferred tax liabilities on balance sheet ($M)($M) | 0 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 3.12 | 3.12 | 3.12 | 3.12 | |
Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index)1 | |||||||||||||
U.S. Personal Consumption Expenditures: Health Care Services, SAAR ($B) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Income Statement — Total revenue ($M)($M)18 | 198 | 0 | 0 | 0 | 0 | 0 | 0 | 0.74 | |||||
Research and development expense ($M)($M) | 417 | 395 | 344 | 295 | 263 | 224 | 206 | 188 | 152 | 135 | 118 | 148 | |
Selling, general and administrative expense ($M)($M) | 153 | 110 | 101 | 66.7 | 52.8 | 40.6 | 35.0 | 28.2 | 24.0 | 21.7 | 22.8 | 32.2 | |
Total operating expenses ($M)($M) | 571 | 505 | 445 | 362 | 315 | 265 | 241 | 216 | 176 | 157 | 141 | 181 | |
Asset impairment charges ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.76 | 0 | 0 | 2.76 | 0 | |
Gain (loss) on sale of assets ($M)($M) | 0 | -0.03 | 0 | 0 | 0.20 | -0.20 | -0.04 | -0.07 | -0.05 | ||||
Operating loss ($M)($M) | -373 | -505 | -445 | -362 | -315 | -265 | -241 | -216 | -176 | -157 | -141 | -180 | |
Interest and investment income ($M)($M) | 37.8 | 35.6 | 19.5 | 21.3 | 22.1 | 22.4 | 24.9 | 21.2 | 20.4 | 21.5 | 23.8 | 19.0 | |
Interest expense ($M)($M) | 33.8 | 23.8 | 12.2 | 11.9 | 11.4 | 0.87 | 0 | 0 | 0 | ||||
Other non-operating income (expense), net ($M)($M) | -36.7 | -139 | -8.59 | -3.27 | 10.1 | 16.9 | 27.3 | 21.0 | 19.4 | 23.4 | 24.9 | 18.8 | |
Loss before income taxes ($M)($M) | -410 | -644 | -454 | -365 | -305 | -248 | -213 | -195 | -156 | -133 | -116 | -161 | |
Provision for (benefit from) income taxes ($M)($M) | -2.35 | 0 | 0 | -0.75 | 0 | 0 | 0 | 0.34 | |||||
Net loss ($M)($M) | -407 | -644 | -454 | -365 | -305 | -248 | -213 | -195 | -156 | -133 | -116 | -162 | |
Net loss attributable to common stockholders ($M)($M) | -407 | -644 | -454 | -365 | -305 | -248 | -213 | -195 | -156 | -133 | -116 | -162 | |
Consolidated net loss ($M)($M) | -407 | -644 | -454 | -365 | -305 | -248 | -213 | -195 | -156 | -133 | -116 | -162 | |
Net loss per share — Basic ($/sh)($) | -1.90 | -3.06 | -2.29 | -1.61 | -1.31 | -1.13 | -0.94 | -0.81 | -0.70 | ||||
Net loss per share — Diluted ($/sh)($) | -1.90 | -3.06 | -2.29 | -1.61 | -1.31 | -1.13 | -0.94 | -0.81 | -0.70 | ||||
Weighted-average basic shares outstanding (M shares)(M) | 215 | 211 | 198 | 189 | 189 | 188 | 167 | 165 | 165 | ||||
Weighted-average diluted shares outstanding (M shares)(M) | 215 | 211 | 198 | 189 | 189 | 188 | 167 | 165 | 165 | ||||
Balance Sheet — Total assets ($M)($M)29 | 4,304 | 4,323 | 2,254 | 2,355 | 2,252 | 2,430 | 2,365 | 2,558 | 1,763 | 1,808 | 1,908 | 2,062 | |
Cash and cash equivalents ($M)($M) | 616 | 815 | 441 | 384 | 217 | 402 | 334 | 543 | 201 | 276 | 288 | 696 | |
Short-term marketable securities ($M)($M) | 3,035 | 3,123 | 1,467 | 1,642 | 1,714 | 1,735 | 1,769 | 1,746 | 1,348 | 1,315 | 1,415 | 1,157 | |
Prepaid expenses and other current assets ($M)($M) | 83.6 | 90.4 | 59.8 | 49.4 | 46.0 | 39.3 | 31.9 | 38.3 | 29.7 | 34.0 | 25.7 | 25.1 | |
Total current assets ($M)($M) | 3,977 | 4,028 | 1,968 | 2,075 | 1,977 | 2,176 | 2,135 | 2,328 | 1,579 | 1,625 | 1,729 | 1,879 | |
Property and equipment, gross ($M)($M) | 69.7 | 67.5 | 62.2 | 61.7 | 59.9 | 58.1 | 50.5 | 46.1 | 46.5 | 45.7 | 42.6 | 40.6 | |
Accumulated depreciation ($M)($M) | -35.1 | -32.8 | -30.7 | -28.5 | -27.0 | -25.0 | -23.4 | -21.8 | -21.7 | -20.5 | -18.9 | -17.7 | |
Property and equipment, net ($M)($M) | 34.6 | 34.6 | 31.5 | 33.2 | 32.9 | 33.1 | 27.2 | 24.3 | 24.8 | 25.3 | 23.7 | 22.9 | |
Operating lease right-of-use assets ($M)($M) | 125 | 128 | 130 | 132 | 134 | 114 | 116 | 118 | 74.3 | 75.3 | 76.2 | 77.2 | |
Goodwill ($M)($M) | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | |
Intangible assets, net ($M)($M) | 55.5 | 55.8 | 55.8 | 55.8 | 55.9 | 56.1 | 56.4 | 56.7 | 56.9 | 57.2 | 57.5 | 57.7 | |
Other non-current assets ($M)($M) | 15.2 | 14.8 | 14.5 | 14.8 | 14.9 | 31.4 | 13.1 | 1.74 | 10.3 | 8.27 | 4.16 | 7.03 | |
Accounts payable ($M)($M) | 101 | 88.4 | 80.5 | 64.6 | 74.9 | 56.8 | 47.5 | 54.4 | 24.5 | 29.3 | 32.4 | 61.8 | |
Operating lease liabilities, current ($M)($M) | 9.38 | 16.8 | 16.6 | 16.5 | 16.3 | 13.1 | 13.0 | 12.9 | 8.40 | 8.33 | 8.17 | 7.37 | |
Accrued expenses and other current liabilities ($M)($M) | 22.7 | 5.14 | 3.26 | 7.86 | 8.24 | 0.46 | 0.65 | 0.58 | 1.28 | 0.66 | 0.74 | 3.90 | |
Total current liabilities ($M)($M) | 476 | 354 | 290 | 290 | 246 | 185 | 159 | 164 | 111 | 105 | 93.7 | 144 | |
Operating lease liabilities, non-current ($M)($M) | 142 | 138 | 140 | 142 | 142 | 120 | 121 | 123 | 78.3 | 79.1 | 79.9 | 80.6 | |
Total operating lease liabilities ($M)($M) | 151 | 154 | 157 | 159 | 158 | 133 | 134 | 136 | 86.7 | 87.4 | 88.0 | 87.9 | |
Deferred tax liabilities ($M)($M) | 0 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 3.11 | 3.11 | 3.11 | 3.11 | |
Other non-current liabilities ($M)($M) | 0 | 1.65 | 6.88 | 1.21 | 2.48 | 7.20 | 4.14 | 0.67 | 1.64 | 0.66 | 3.04 | 1.46 | |
Total liabilities ($M)($M) | 1,902 | 1,717 | 754 | 723 | 655 | 564 | 287 | 293 | 197 | 190 | 183 | 236 | |
Preferred stock ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Common stock ($M)($M) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Additional paid-in capital ($M)($M) | 6,791 | 6,579 | 4,823 | 4,497 | 4,098 | 4,063 | 4,028 | 4,002 | 3,106 | 3,008 | 2,980 | 2,963 | |
Accumulated deficit ($M)($M) | -4,375 | -3,967 | -3,323 | -2,869 | -2,504 | -2,199 | -1,951 | -1,738 | -1,543 | -1,387 | -1,254 | -1,138 | |
Accumulated other comprehensive income (loss) ($M)($M) | -14.7 | -5.95 | -0.62 | 3.24 | 3.12 | 1.30 | 1.71 | 1.32 | 3.81 | -1.86 | -1.20 | 0.54 | |
Stockholders' equity ($M)($M) | 2,402 | 2,606 | 1,500 | 1,631 | 1,597 | 1,865 | 2,078 | 2,265 | 1,566 | 1,619 | 1,725 | 1,826 | |
Total equity ($M)($M) | 2,402 | 2,606 | 1,500 | 1,631 | 1,597 | 1,865 | 2,078 | 2,265 | 1,566 | 1,619 | 1,725 | 1,826 | |
Total liabilities and stockholders' equity ($M)($M) | 4,304 | 4,323 | 2,254 | 2,355 | 2,252 | 2,430 | 2,365 | 2,558 | 1,763 | 1,808 | 1,908 | 2,062 | |
Common shares outstanding at period-end (M shares)(M) | 216 | 214 | 200 | 197 | 190 | 187 | 186 | 186 | 168 | 166 | 165 | 165 | |
Cash Flow Statement — Operating cash flow ($M)($M)12 | -416 | -387 | -354 | -274 | -207 | -222 | -194 | -138 | -130 | -128 | -161 | -121 | |
Depreciation and amortization ($M)($M) | 2.63 | 2.45 | 2.35 | 2.27 | 1.53 | 2.29 | 1.69 | 1.73 | 1.64 | 1.64 | 1.54 | ||
Stock-based compensation ($M)($M) | 62.2 | 67 | 87.3 | 33.7 | 30.8 | 28.8 | 25.1 | 22.4 | 20.8 | 19.8 | 16.2 | 25.4 | |
Change in deferred revenue ($M)($M) | 0 | 0 | 0 | 0 | 0 | ||||||||
Change in accounts receivable ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.25 | -0.94 | ||||
Change in accounts payable ($M)($M) | 13.8 | 5.03 | 16.9 | -10.5 | 19.5 | 8.76 | -8.27 | 29.4 | -2.79 | -4.08 | -29.0 | 24.3 | |
Capital expenditures ($M)($M) | 3.70 | 2.29 | 1.54 | 1.92 | 3.35 | 7.45 | 3.27 | 1.22 | 3.52 | 2.40 | 3.17 | 2.32 | |
Purchases of marketable securities ($M)($M) | 541 | 2,038 | 210 | 296 | 459 | 529 | 510 | 695 | 365 | 375 | 702 | 520 | |
Proceeds from maturities and sales of marketable securities ($M)($M) | 9.44 | 0 | 0 | 0 | 0 | ||||||||
Net cash provided by (used in) investing activities ($M)($M) | 80.1 | -1,659 | 173 | 74.9 | 24.9 | 34.3 | -16.0 | -393 | -21.5 | 108 | -248 | -380 | |
Proceeds from issuance of common stock ($M)($M) | 0 | 0 | 0 | 728 | 0 | 0 | 0 | 0 | |||||
Net cash provided by financing activities ($M)($M) | 147 | 2,420 | 239 | 366 | -1.59 | 257 | 0.87 | 874 | 77.3 | 7.50 | 0.81 | 839 | |
Net increase (decrease) in cash, cash equivalents and restricted cash ($M)($M) | -189 | 375 | 57.2 | 166 | -184 | 69.1 | -210 | 343 | -74.6 | -12.7 | -408 | 338 | |
40 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & single-segment structure: Revolution Medicines, Inc. (NASDAQ: RVMD, CIK 0001628171) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026; Q3 2026 ended September 30, 2026) and manages its business as a single global operating segment focused on targeted therapies for RAS-addicted cancers. On August 5, 2026 (during Q3 2026), the U.S. FDA approved RVMD's first commercial medicine, RASONQUE (daraxonrasib / RMC-6236), for adults with previously treated locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring a KRAS G12X, G13D, or Q61H mutation.
- Core operational & R&D KPIs (Groups 1–3) cover: (1) Clinical Trial Pipeline & Patient Enrollment Funnel (Key #1) tracked via ClinicalTrials.gov API v2 across 33 registered RAS(ON) clinical studies and 6,928 cumulative target/actual patients through Q3 2026, broken down by phase (7 Phase 3 registrational trials — RASolute 302/303/304/305/309, RASolve 301 & RAS-002 — encompassing 3,845 target patients; 14 Phase 1/2 & Phase 2 trials; 12 Phase 1 trials), sponsor (24 RVMD-sponsored vs. 9 partner-sponsored), and drug candidate (Daraxonrasib 14 studies / 5,112 patients, Zoldonrasib 8 studies / 3,240 patients, Elironrasib 4 studies / 719 patients, RMC-5127 2 studies / 210 patients, and RAS companion inhibitors RMC-4630/RMC-4550 9 studies / 950 patients); (2) R&D Investment by Drug Candidate, Cost Nature & Full-Year Guidance (Key #2) across 15 consecutive quarters (Q1 2023–Q3 2026) and 4 years (FY2022–FY2025), disaggregating GAAP R&D ($975.1M in FY2025; $265.1M in Q3 2026) into External Third-Party R&D ($561.7M in FY2025; $155.1M in Q3 2026 across Daraxonrasib $87.9M, Zoldonrasib $32.2M, Elironrasib $5.7M, RMC-5127 $5.7M, and Preclinical $23.5M in Q3 2026) and Internal Unallocated R&D (Salaries & Benefits $59.7M, SBC $25.8M, Intangible Amortization $0.3M, and Facilities/Other $24.2M in Q3 2026), plus 24 consecutive quarterly management guidance snapshots (Q4 2020–Q3 2026); and (3) Royalty Pharma Synthetic Royalty Monetization ($550.0M carrying liability at Q3 2026 following receipt of the initial $250.0M Phase 3 tranche in Q2 2025 and the $250.0M FDA approval tranche in Q3 2026), 2033 Convertible Senior Notes ($844.0M carrying value at Q3 2026), and assumed EQRx public/private warrant liabilities ($54.0M fair value at Q3 2026).
- Subsidiary, Treasury, Equity, Facilities & Workforce KPIs (Groups 4–9) cover: (4) Acquired Subsidiary EQRx, Inc. (EQRx, LLC, CIK 0001843762) standalone pre-acquisition operations (FY2020–Q3 2023 prior to the November 9, 2023 acquisition close), including standalone R&D disaggregation across aumolertinib, sugemalimab, lerociclib, nofazinlimab, EQ121, and preclinical programs, standalone cash & marketable securities ($1,226.4M at Q3 2023), and standalone workforce; (5) Cash & AFS Marketable Debt Portfolio ($2,911.0M fair value and $2,908.3M amortized cost at Q3 2026 broken down across U.S. government & agency debt, commercial paper, corporate debt, and money market funds, maturity buckets, and Level 1–3 fair value hierarchy); (6) Equity Incentive Plans, Stock Options (10.72M outstanding at $29.66 WAEP and $634.3M intrinsic value at Q3 2026), RSUs/PSUs (5.16M unvested at $45.39 WAFV and $457.8M intrinsic value at Q3 2026), ATM equity offerings, and antidilutive securities (22.74M total excluded shares at Q3 2026); (7) Operating Leases ($117.7M lease liability across 7.10 years weighted-average remaining term at 8.15% discount rate), PP&E by asset class, Goodwill & Intangibles, Accrued Liabilities breakdown, and Deferred Tax Assets ($652.1M gross DTA fully offset by a $616.5M valuation allowance at FY2025); (8) Human Capital (638 full-time employees including 443 in R&D and 233 holding Ph.D./M.D. degrees at FY2025), CEO Pay Ratio & Pay Versus Performance; and (9) FRED Pharmaceutical & Healthcare Benchmarks and Core Financial Statements from the database.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed; instead, acquired subsidiary EQRx, Inc.'s pre-acquisition standalone filings (CIK 0001843762) are presented directly in Group 4. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (6)
- RASONQUE (daraxonrasib) commercial net product revenue ($4.3M in Q3 2026), Cost of Sales ($0.5M in Q3 2026), Customer concentration (% of Q3 2026 revenue from Customer One 39% and Customer Two 35%), Accrued commercial rebates ($1.4M at Q3 2026), and Commercial inventory by stage (Raw Materials $10.0M, WIP $23.1M, Finished Goods $3.6M, Total Net Inventory $36.7M at Q3 2026): FDA approved RASONQUE on August 5, 2026 (during Q3 2026), so commercial product sales, inventory capitalization, and GTN rebates have only 1 active commercial quarter (Q3 2026, plus $0 comparative at Q4 2025), fewer than the required 3 consecutive quarters.
- RASONQUE commercial launch operational callouts from Q3 2026 earnings release & transcript (185 target health systems, 60% initial launch formulary adoption rate, 80% coverage across top 50 academic accounts, 70% initial prescription share in 2L+ PDAC): single-quarter initial launch snapshot in Q3 2026 (< 3 consecutive periods).
- 2033 Convertible Senior Notes face value ($862.5M) and unamortized debt issuance costs ($19.4M at Q3 2026): issued in June 2026 (Q2 2026), providing only 2 quarterly data points (Q2 2026 and Q3 2026) for the separate face/unamortized footnote breakdown (< 3 consecutive quarters); carrying value is included via the balance sheet convertible notes series.
- Clinical trial objective response rates (ORR), disease control rates (DCR), median progression-free survival (mPFS), and median overall survival (mOS) for daraxonrasib, zoldonrasib, elironrasib, and RMC-5127: cohort-specific clinical readouts rather than recurring periodic operational time series.
- Approximate / bound-only disclosures ('more than 2,500 patients treated', 'over 600 employees', 'up to $1.25 billion'): excluded per strict point-value rule (lib.quotes.is_bound).
- Self-computed ratios, margins, YoY/QoQ growth percentages, and component sums not explicitly published by Revolution Medicines: excluded per strict derivation rule (only Q4 = FY - 9M and Q = YTD - prior YTD period splits are permitted).
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Clinical Trial Pipeline & Patient Enrollment Funnel (Key #1)
R&D Investment by Drug Candidate, Cost Nature & Full-Year Guidance (Key #2)
Royalty Pharma Monetization, Convertible Senior Notes & Warrant Liabilities
Acquired Subsidiary — EQRx, Inc. (EQRx, LLC) Standalone Pre-Acquisition Operations & R&D Pipeline
Cash, Cash Equivalents & Available-for-Sale (AFS) Marketable Debt Portfolio
- Cash equivalents & AFS marketable securities portfolio — Total fair value ($M) ($M)28 kỳ
- Cash equivalents & AFS marketable securities portfolio — Total amortized cost ($M) ($M)28 kỳ
- Financial assets measured at fair value on a recurring basis — Total ($M) ($M)28 kỳ
- Cash, cash equivalents and restricted cash — Ending balance ($M) ($M)32 kỳ
Equity Incentive Plans, Stock Options, RSUs, ATM Offerings & Antidilutive Securities
- Total stock-based compensation (SBC) expense ($M) ($M)31 kỳ
- Stock options outstanding — Ending shares (M shares) (M)29 kỳ
- Nonvested restricted stock units (RSUs & PSUs) outstanding — Ending shares (M shares) (M)26 kỳ
- Common stock reserved for future issuance — Total across all plans & warrants (M shares) (M)28 kỳ
- Potentially dilutive securities excluded from diluted net loss per share — Total (M shares) (M)32 kỳ
Facilities, Operating Leases, PP&E, Intangibles, Accrued Liabilities & Income Taxes
- Operating lease liabilities — Total carrying value ($M) ($M)27 kỳ
- Property and equipment, net ($M) ($M)28 kỳ
- Goodwill & acquired intangible assets — Total net intangible assets ($M) ($M)28 kỳ
- Accrued expenses and other current liabilities — Total ($M) ($M)28 kỳ
- Income taxes — Gross deferred tax assets (before valuation allowance) ($M) ($M)7 kỳ
Human Capital, Scientific Talent, Diversity & Executive Pay Versus Performance
Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Revolution Medicines
- Form 10-Q (filed 2026-11-04) ↗
- Form 10-K (filed 2026-02-25) ↗
- ClinicalTrials.gov API v2 (Revolution Medicines, Inc.) ↗
- Form 10-K (rvmd-20251231.htm, filed 2026-02-25) ↗
- Form 10-Q (rvmd-20260930.htm, filed 2026-11-04) ↗
- SEC Filing (eqrx-20221231x10k.htm) ↗
- SEC Filing ↗
- SEC Filing ↗
- Form 8-K (rvmd-ex99_1.htm, filed 2026-11-04) ↗
- SEC Filing (eqrx-20230930x10q.htm) ↗
- Proxy Statement (DEF 14A) (d111313ddef14a.htm, filed 2026-04-27) ↗
- FRED (PCU325412325412) ↗
See a number that looks wrong?